慢性髓性白血病：生物学与治疗

IF 6.9 2区医学 Q1 HEMATOLOGY

Blood Reviews Pub Date : 2024-03-27 DOI:10.1016/j.blre.2024.101196

Yun Wang , Zhi-jian Liang , Robert Peter Gale , Hua-ze Liao , Jun Ma , Tie-jun Gong , Ying-qi Shao , Yang Liang

{"title":"慢性髓性白血病：生物学与治疗","authors":"Yun Wang , Zhi-jian Liang , Robert Peter Gale , Hua-ze Liao , Jun Ma , Tie-jun Gong , Ying-qi Shao , Yang Liang","doi":"10.1016/j.blre.2024.101196","DOIUrl":null,"url":null,"abstract":"<div><p>Chronic myeloid leukaemia (CML) is caused by <em>BCR::ABL1</em>. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the <em>optimal</em> therapy goal. Which TKI is the <em>best</em> initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"65 ","pages":"Article 101196"},"PeriodicalIF":6.9000,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chronic myeloid leukaemia: Biology and therapy\",\"authors\":\"Yun Wang , Zhi-jian Liang , Robert Peter Gale , Hua-ze Liao , Jun Ma , Tie-jun Gong , Ying-qi Shao , Yang Liang\",\"doi\":\"10.1016/j.blre.2024.101196\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Chronic myeloid leukaemia (CML) is caused by <em>BCR::ABL1</em>. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the <em>optimal</em> therapy goal. Which TKI is the <em>best</em> initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.</p></div>\",\"PeriodicalId\":56139,\"journal\":{\"name\":\"Blood Reviews\",\"volume\":\"65 \",\"pages\":\"Article 101196\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0268960X24000298\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X24000298","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

慢性髓性白血病（CML）是由BCR::ABL1引起的。酪氨酸激酶抑制剂（TKIs）是初始疗法。一些组织报告了评估初始 TKI 治疗反应的里程碑，并建议何时应考虑更换 TKI。实现无治疗缓解（TFR）越来越被认为是最佳治疗目标。哪种 TKI 是针对哪些患者的最佳初始疗法，以及实现 TFR 所需的分子缓解深度和持续时间都存在争议。在这篇综述中，我们将讨论这些问题并提出未来的研究方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Chronic myeloid leukaemia: Biology and therapy

Chronic myeloid leukaemia (CML) is caused by BCR::ABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the optimal therapy goal. Which TKI is the best initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood Reviews 医学-血液学

CiteScore

13.80

自引率

1.40%

发文量

期刊介绍： Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.